$7.15
(Market cap
$6,410 Mln
Revenue (TTM)
$551 Mln
P/E Ratio
--
P/B Ratio
9.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
50.52
-
EV/EBITDA
-57.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.3
-
Face value
--
-
Shares outstanding
58,733,911
10 Years Aggregate
CFO
$-42.10 Mln
EBITDA
$-439.10 Mln
Net Profit
$-446.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
| -2.3 | -21.4 | -8.4 | 16.9 | 23.3 | 8.6 | 16.3 |
|
BSE Sensex
| -11.8 | -2.9 | -8.2 | -8.4 | 6.1 | 7.5 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
| -24.7 | 87.7 | 82.0 | -1.7 | -41.0 | 38.2 | -3.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glaukos Corp (GKOS)
|
110.3 | 6,409.9 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 9.6 |
| 8.9 | 6,247.2 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 304.2 | 8,139.5 | 2,589.9 | 168.8 | 21.4 | 2.5 | 50.5 | 1.2 | |
| 57.2 | 8,964.6 | 3,458.5 | -11.6 | 2.6 | -0.6 | -- | 3.0 | |
| 104.8 | 3,743.0 | 787.9 | -27.8 | -2.7 | -19.6 | -- | 22.7 | |
| 96.6 | 6,465.0 | 1,546.2 | 279.0 | 15.0 | 23.9 | 23.7 | 5.3 | |
| 178.7 | 9,345.3 | 1,558.5 | 76.3 | 19.6 | 9.5 | 44.3 | 11.9 | |
| 60.9 | 3,761.8 | 1,542.8 | 139.3 | 12.1 | 8.8 | 27.2 | 2.3 | |
| 318.9 | 12,561.0 | 1,454.3 | 171.1 | 11.1 | 12.1 | 73.9 | 8.5 | |
| 121.0 | 6,991.7 | 763.3 | 51.4 | 11.7 | 2.5 | 137.7 | 3.0 |
Shareholding Pattern
View DetailsAbout Glaukos Corp (GKOS)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W... micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Read more
-
Chairman & CEO
Mr. Thomas William Burns
-
Chairman & CEO
Mr. Thomas William Burns
-
Headquarters
Aliso Viejo, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Glaukos Corp (GKOS)
What is the current share price of Glaukos Corp (GKOS) Today?
The share price of Glaukos Corp (GKOS) is $110.27 (NYSE) as of 02-Jun-2026 14:50 EDT. Glaukos Corp (GKOS) has given a return of 23.3% in the last 3 years.
What is the current PB & PE ratio of Glaukos Corp (GKOS)?
Since, TTM earnings of Glaukos Corp (GKOS) is negative, P/E ratio is not available.
The P/B ratio of Glaukos Corp (GKOS) is 9.62 times as on 29-May-2026, a 217 premium to its peers’ median range of 3.03 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-34.59
|
9.90
|
|
2024
|
-56.94
|
10.87
|
|
2023
|
-28.85
|
8.41
|
|
2022
|
-21.02
|
3.93
|
|
2021
|
-42.05
|
3.55
|
What is the 52 Week High and Low of Glaukos Corp (GKOS)?
The 52-week high and low of Glaukos Corp (GKOS) are Rs 148.11 and Rs 73.16 as of 03-Jun-2026.
What is the market cap of Glaukos Corp (GKOS)?
Glaukos Corp (GKOS) has a market capitalisation of $ 6,410 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Glaukos Corp (GKOS)?
Before investing in Glaukos Corp (GKOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.